An odyssey from breast to bone: Multi-step control of mammary metastases and osteolysis by matrix metalloproteinases

APMIS

Volumn 107, Issue 1, 1999, Pages 128-136

  Lochter, André ^a   Bissell, Mina J ^b  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone resorption; Breast cancer; Collagenase; Invasion; Migration; Stromelysin l; Transdifferentiation

Indexed keywords

COLLAGENASE; STROMELYSIN;

BONE METASTASIS; BREAST CANCER; CANCER INVASION; CELL DIFFERENTIATION; CELL MIGRATION; ENZYME ACTIVITY; METASTASIS POTENTIAL; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033039398     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01535.x     Document Type: Review

References (96)

1. 1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. 2. Dankort DL, Muller WJ. Transgenic models of breast cancer metastasis. Cancer Treat Res 1996;83:71-88.
3. 3. Webster MA, Muller WJ. Mammary tumorigenesis and metastasis in transgenic mice. Semin Cancer Biol 1994;5:69-76.
4. 4. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269:16766-73.
5. 5. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996;56:944-9.
6. 6. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704.
7. 7. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91:439-42.
8. 8. Feller WF, Stewart SE, Kantor J. Primary tissue culture explants of human breast cancer. J Natl Cancer Inst 1972;48:1117-20.
9. 9. Langer E, Keiditsch E, Strauch L, Hannig K. Die Kollagenaseaktivität im carcinoma solidum simplex mammae. Verh Dtsch Ges Pathol 1968;52:438-41.
10. 10. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14:351-62.
11. 11. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
12. 12. Soini Y, Hurskainen T, Hoyhtya M, Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994;42:945-51.
13. 13. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-60.
14. 14. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-36.
15. 15. Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69:448-51.
16. 16. Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP, et al. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1994; 14:269-75.
17. 17. Matrisian LM, Bowden GT. Stromelysin/transin and tumor progression. Semin Cancer Biol 1990;1:107-15.
18. 18. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993; 24:209-18.
19. 19. Polette M, Nawrocki B, Gilles C, Sato H, Seiki M, Tournier JM, et al. MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 1996;428:29-35.
20. 20. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76:69-125.
21. 21. Lochter A, Bissell MJ. Involvement of extracellular matrix constituents in breast cancer. Semin Cancer Biol 1995;6:165-73.
22. 22. Flug M, Kopf-Maier P. The basement membrane and its involvement in carcinoma cell invasion. Acta Anat (Basel) 1995;152:69-84.
23. 23. Body JJ. Clinical trials in metastatic breast cancer to bone: past - present - future. Can J Oncol 1995; 5 (Suppl 1): 16-27.
24. 24. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
25. 25. Walther HE. Krebsmetastasen. Bens Schwabe Verlag. Switzerland. 1948.
26. 26. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986;261:12665-74.
27. 27. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80:1546-56.
28. 28. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997;12:869-79.
29. 29. Aubin JE, Liu F, Malaval L, Gupta AK. Osteoblast and chondroblast differentiation. Bone 1995;17:77S-83S.
30. 30. Fuller K, Owens J, Chambers TJ. The effect of hepatocyte growth factor on the behaviour of osteoclasts. Biochem Biophys Res Commun 1995;212:334-40.
31. 31. Scholl SM, Crocker P, Tang R, Pouillart P, Pollard JW. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol Carcinog 1993; 7:207-11.
32. 32. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
33. 33. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
34. 34. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
35. 35. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-74.
36. 36. Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z, Bissell MJ. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem 1997;272:5007-15.
37. 37. Lochter A, Sternlicht MD, Werb Z, Bissell MJ. The significance of matrix metalloproteinases during early stages of tumor progression. Ann NY Acad Sci 1998; 857:101-18.
38. 38. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8.
39. 39. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99:2509-17.
40. 40. Masson R, Lefebvre O, No, Fahime ME, Chenard MP, Wendung C, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-41.
41. 41. Noel AC, Lefebvre O, Maquoi E, VanHoorde L, Chenard MP, Marcel M, et al. Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 1996; 97:1924-30.
42. 42. Sledge GWJ, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995;87:1546-50.
43. 43. Sympson CJ, Bissell MJ, Werb Z. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 1995;6:159-63.
44. 44. Thomasset N, Lochter A, Sympson CJ, Lund LR, Williams PJ, Behrendtsen O, et al., Expression of autoactivated stromelyin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol 1998;153:457-67.
45. 45. Yoshida T, Ishihara A, Hirokawa Y, Kusakabe M, Sakakura T. Tenascin in breast cancer development - is epithelial tenascin a marker for poor prognosis? Cancer Lett 1995;90:65-73.
46. 46. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 1987;84:4621-5.
47. 47. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
48. 48. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180-9.
49. 49. Schor SL, Schor AM, Howell A, Crowther D. Hypothesis: persistent expression of fetal phenotypic characteristics by fibroblasts is associated with an increased susceptibility to neoplastic disease. Exp Cell Biol 1987; 55:11-7.
50. 50. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a pre-malignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-72.
51. 51. Kitsberg DI, Leder P. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 1996;13:2507-15.
52. 52. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382:638-42.
53. 53. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806-11.
54. 54. Witty JP, Lempka T, Coffey RJJ, Matrisian LM. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 1995;55:1401-6.
55. 55. Lochter A, Bissell MJ. Mammary gland biology and the wisdom of extracellular matrix. In: Wilde CJ, Peaker M, Taylor E, editors. Biological signaling and the mammary gland. Ayr. UK. 1997: p. 77-92.
56. 56. Bissell MJ. The central role of basement membrane in functional differentiation apoptosis and cancer. In: Cell Death in Reproductive Physiology. Tilly JF, Strauss III JF, Tenniswood H, editors. Sereno Symposia USA 1997; pp. 125-40.
57. 57. Hagios C, Lochter A, Bissell MJ. Tissue structure: the ultimate regulator of epithelial function? Phil Transactions Roy Soc Lond 1998; in press.
58. 58. Manishen WJ, Sivananthan K, Orr FW. Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Pathol 1986; 123:39-45.
59. 59. Giunciuglio D, Cai T, Filanti C, Manduca P, Albini A. Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer Lett 1995;97:69-74.
60. 60. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978;276:726-8.
61. 61. Horton JE, Wezeman FH, Kuettner KE. Inhibition of bone resorption in vitro by a cartilage-derived anticollagenase factor. Science 1978;199:1342-5.
62. 62. Hill PA, Reynolds JJ, Meikle MC. Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2. Biochim Biophys Acta 1993;1177:71-4.
63. 63. Shimizu H, Sakamoto M, Sakamoto S. Bone resorption by isolated osteoclasts in living versus devitalized bone: differences in mode and extent and the effects of human recombinant tissue inhibitor of metalloproteinases. J Bone Miner Res 1990;5:411-8.
64. 64. Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 1997;272:22053-8.
65. 65. Witty JP, Foster SA, Stricklin GP, Matrisian LM, Stern PH. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. J Bone Miner Res 1996;11:72-8.
66. 66. Delaisse JM, Eeckhout Y, Sear C, Galloway A, McCullagh K, Vaes G. A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture. Biochem Biophys Res Commun 1985;133:483-90.
67. 67. Hill PA, Murphy G, Docherty AJ, Hembry RM, Millican TA, Reynolds JJ, et al. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 1994;107:3055-64.
68. 68. Hill PA, Docherty AJ, Bottomley KM, O'Connell JP, Morphy JR, Reynolds JJ, et al. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J 1995;308:167-75.
69. 69. Delaisse JM, Boyde A, Maconnachie E, Ali NN, Sear CH, Eeckhout Y, et al. The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts. Bone 1987;8:305-13.
70. 70. Fuller K, Chambers TJ. Localisation of mRNA for collagenase in osteocytic, bone surface and chondrocytic cells but not osteoclasts. J Cell Sci 1995;108:2221-30.
71. 71. Sato T, Foged NT, Delaisse JM. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res 1998; 13:59-66.
72. 72. Everts V, Delaisse JM, Korper W, Niehof A, Vaes G, Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 1992;150:221-31.
73. 73. Everts V, Delaisse JM, Korper W, Beertsen W. Involvement of matrix metalloproteinases and cysteine proteinases in degradation of bone matrix. In: Davidovitch Z, editor. The biological mechanism of tooth eruption, resorption and replacement by implants. 1994. p85-97.
74. 74. Eeckhout Y. Possible role and mechanism of action of dissolved calcium in the degradation of bone collagen by lysosomal cathepsins and collagenase. Biochem J 1990;272:529-32.
75. 75. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 1995;72:311-22.
76. 76. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990;194:721-30.
77. 77. Blavier L, Delaisse JM. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 1995;108:3649-59.
78. 78. Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K. High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 1994;124:1091-102.
79. 79. Meikle MC, Bord S, Hembry RM, Compston J, Croucher PI, Reynolds JJ. Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. J Cell Sci 1992;103:1093-9.
80. 80. Malone JD, Teitelbaum SL, Griffin GL, Senior RM, Kahn AJ. Recruitment of osteoclast precursors by purified bone matrix constituents. J Cell Biol 1982;92:227-30.
81. 81. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-9.
82. 82. Partridge NC, Walling HW, Bloch SR, Omura TH, Chan PT, Pearman AT, et al. The regulation and regulatory role of collagenase in bone. Crit Rev Eukaryot Gene Expr 1996;6:15-27.
83. 83. Chambers TJ, Fuller K. Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 1985;76:155-65.
84. 84. Delaisse JM, Eeckhout Y, Neff L, Francois-Gillet C, Henriet P, Su Y, et al. (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment. J Cell Sci 1993;106:1071-82.
85. 85. Rodan SB, Rodan GA. Integrin function in osteoclasts. J Endocrinol 1997; 154 Suppl: S47-S56.
86. 86. Raynal C, Delmas PD, Chenu C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 1996;137:2347-54.
87. 87. Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994;54:2823-6.
88. 88. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996;13:97-104.
89. 89. Ohishi K, Fujita N, Morinaga Y, Tsuruo T. H-31 human breast cancer cells stimulate type I collagenase production in osteoblasl-like cells and induce bone resorption. Clin Exp Metastasis 1995;13:287-95.
90. 90. Mundy GR, DeMartino S, Rowe DW. Collagen and collagen-derived fragments are chemotactic for tumor cells. J Clin Invest 1981;68:1102-5.
91. 91. Chen WT. Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Enzyme Protein 1996;49:59-71.
92. 92. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997;15:175-85.
93. 93. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
94. 94. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997;80:1668-73.
95. 95. Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, et al. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif Tissue Int 1997;61:59-61.
96. 96. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116-31.